Jinli Jian
Overview
Explore the profile of Jinli Jian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
31
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guo Y, Jian J, Tang X, Zhao L, Liu B
Anticancer Drugs
. 2025 Jan;
36(3):199-207.
PMID: 39786970
This study investigated whether the neddylation inhibitor MLN4924 induces aberrant DNA methylation patterns in acute myeloid leukemia and contributes to the reactivation of tumor suppressor genes. DNA methylation profiles of...
2.
Guo Y, Niu Y, Liang H, Yang X, Jian J, Tang X, et al.
Transl Cancer Res
. 2024 Jan;
12(12):3432-3442.
PMID: 38192982
Background: The high clinical and molecular heterogeneity of acute myeloid leukemia (AML) has led to an unsatisfactory clinical prognosis, thus we sought to incorporate both clinical features and molecular abnormalities...
3.
Tang X, Niu Y, Jian J, Guo Y, Wang Y, Zhu Y, et al.
Crit Rev Oncol Hematol
. 2023 Nov;
193:104203.
PMID: 37979734
Ferroptosis, a novel form of iron-dependent cell death, has emerged as a potential avenue for promoting tumor cell death by causing cell membrane rupture and the accumulation of lipid peroxides...
4.
Zhu Y, Jian J, Niu Y, Yang X, Guo Y, Zhao L, et al.
Hematology
. 2023 Jul;
28(1):2231760.
PMID: 37417449
Background: This study aimed to investigate the potential of a NAD metabolism-related lncRNA signature as a reliable prognostic biomarker for acute myeloid leukemia (AML). Methods: Transcriptome profiles and clinical data...
5.
Liang H, Feng Y, Guo Y, Jian J, Zhao L, Luo X, et al.
Front Oncol
. 2022 Oct;
12:1014504.
PMID: 36313674
Background: Somatic mutations are widespread in patients with Myelodysplastic Syndrome (MDS) and are associated with prognosis. However, a practical prognostic model for MDS that incorporates somatic mutations urgently needs to...
6.
Qiao Y, Jian J, Deng L, Tian H, Liu B
Transl Cancer Res
. 2022 Feb;
9(8):4988-4998.
PMID: 35117861
The skin involvement of myeloid leukaemia is conventionally divided into specific malignant lesions and non-specific benign lesions, and these categories are also applicable in chronic myelomonocytic leukaemia (CMML). According to...
7.
Liu B, Guo Y, Deng L, Qiao Y, Jian J
Hematology
. 2020 Nov;
25(1):414-423.
PMID: 33191860
Objectives: To evaluate the efficacy and adverse effects of venetoclax(VEN) in combination with hypomethylating agents(HMAs) in acute myeloid leukemia(AML) or myelodysplastic syndrome(MDS). Methods: Clinical studies were identified from the Cochrane...
8.
Qiao Y, Zhao L, Jian J, Guo Y, Liu B
Br J Hosp Med (Lond)
. 2019 Sep;
80(9):542-543.
PMID: 31498675
No abstract available.
9.
Zhang S, Zhou W, Li Y, Yu S, Xue M, Qiao Y, et al.
Leuk Lymphoma
. 2018 Oct;
60(5):1316-1319.
PMID: 30328750
No abstract available.
10.
Xue M, Cheng J, Zhao J, Zhang S, Jian J, Qiao Y, et al.
Int J Lab Hematol
. 2018 Oct;
41(1):94-101.
PMID: 30285321
Introduction: To confirm the role of additional chromosomal abnormalities (ACAs) and kinase domain (KD) mutations in the progression and outcomes of Chronic myeloid leukaemia (CML) patients and the connection between...